Table 3.
Nutrient | Higher Dietary Nutrient Intake Than Recommended Level, N (%) | Odds Ratio a (95% Confidence Interval (CI)) | p-Value b | ||||
---|---|---|---|---|---|---|---|
Non-Cancer I (N = 19,926) | Non-Cancer II (N = 20,622) | Cancer Survivors (N = 5224) | Non-Cancer I | Non-Cancer II | Cancer Survivors | ||
Total energy | 6392 (32.1) | 6438 (31.2) | 1608 (30.8) | Reference | 0.93 (0.89–0.98) | 0.92 (0.86–0.99) | 0.81 |
Carbohydrate (% of total energy) | 16901 (84.8) | 17649 (85.6) | 4585 (87.8) | 1.01 (0.96–1.08) | 1.21 (1.10–1.33) | <0.001 | |
Fat (% of total energy) | 203 (1.0) | 184 (0.9) | 26 (0.5) | 0.90 (0.73–1.13) | 0.54 (0.35–0.83) | 0.02 | |
Protein | 11117 (55.8) | 11046 (53.6) | 2696 (51.6) | 0.90 (0.86–0.94) | 0.85 (0.79–0.90) | 0.05 | |
Vitamin A | 4429 (22.2) | 4459 (21.6) | 1207 (23.1) | 0.94 (0.89–0.99) | 1.02 (0.95–1.11) | 0.02 | |
Vitamin B1 | 5871 (29.5) | 5670 (27.5) | 1349 (25.8) | 0.92 (0.88–0.97) | 0.86 (0.80–0.93) | 0.08 | |
Vitamin B2 | 3395 (17.0) | 3290 (16.0) | 802 (15.4) | 0.94 (0.89–1.00) | 0.89 (0.81–0.97) | 0.22 | |
Niacin, mg | 8206 (41.2) | 7893 (38.3) | 1976 (37.8) | 0.90 (0.87–0.94) | 0.91 (0.85–0.97) | 0.75 | |
Folate | 1575 (7.9) | 1535 (7.4) | 441 (8.4) | 0.93 (0.86–1.01) | 1.05 (0.93–1.18) | 0.04 | |
Vitamin B6 | 10627 (53.3) | 10624 (51.5) | 2775 (53.1) | 0.93 (0.89–0.97) | 1.01 (0.96–1.08) | 0.01 | |
Vitamin C | 9156 (46.0) | 9347 (45.3) | 2589 (49.6) | 0.98 (0.94–1.03) | 1.16 (1.08–1.23) | <0.001 | |
Calcium | 2162 (10.9) | 2033 (9.9) | 564 (10.8) | 0.89 (0.83–0.96) | 0.96 (0.87–1.07) | 0.15 | |
Phosphorus | 13873 (69.6) | 13802 (66.9) | 3434 (65.7) | 0.89 (0.86–0.94) | 0.86 (0.81–0.92) | 0.22 | |
Iron | 9019 (45.3) | 9579 (46.5) | 2504 (47.9) | 0.98 (0.94–1.03) | 1.05 (0.98–1.13) | 0.045 | |
Zinc | 8714 (43.7) | 8823 (42.8) | 2233 (42.7) | 0.94 (0.90–0.98) | 0.96 (0.89–1.02) | 0.65 |
a Analyses were adjusted for age, marital status, education level, income level, job status, smoking status, drinking status, current physical activity, and body mass index; b Differences between non-cancer individuals with comorbidities and cancer survivors in the Wald test.